SafeHeal

SafeHeal

Paris, France· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

SafeHeal is a French-American medtech company developing the Colovac device, an endoluminal bypass system designed to protect colorectal anastomoses and prevent dangerous post-surgical leaks. The company has achieved European MDR approval for Colovac and is conducting a pivotal IDE study in the U.S., having also received FDA Breakthrough Device designation. Led by an experienced CEO with a commercialization background, SafeHeal is positioned to address a significant unmet need in colorectal surgery recovery, aiming to improve patient outcomes and reduce the burden of temporary ostomies.

SurgeryColorectal Cancer

Technology Platform

Endoluminal bypass sheath technology for the protection of surgical anastomoses from fecal content.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

Large addressable market driven by high incidence of colorectal cancer surgeries and the significant clinical and economic burden of anastomotic leaks and temporary ostomies.
Successful adoption could lead to improved patient quality of life and substantial healthcare cost savings, creating a strong value proposition for payers and providers.

Risk Factors

Clinical trial failure or regulatory delays in the U.S.
pivotal study pose existential risks.
Post-approval, commercial success depends on building an effective sales force, securing favorable reimbursement, and driving surgeon adoption of a new procedural standard.

Competitive Landscape

The market for dedicated anastomosis protection devices is emerging. Competition may come from established surgical sealant and staple line reinforcement products used off-label, or from new entrants developing similar bypass technologies. SafeHeal's first-mover advantage with EU MDR approval and Breakthrough Device designation is a key differentiator.